[JAMA] First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations

dportland Post time 3 day(s) ago | Show all posts |Read mode

Reward20points

journal：JAMA Oncology

Authors：Yusuke Okuma; Kaoru Kubota; Mototsugu Shimokawa; Kana Hashimoto; Yosuke Kawashima; Tomohiro Sakamoto; Hiroshi Wakui; Shuji Murakami; Kyoichi Okishio; Kenji Hayashihara; Yuichiro Ohe;

Published date：2024-1-1

DOI：10.1001/jamaoncol.2023.5013

PDF link：https://jamanetwork.com/journals ... 704491780.96826.pdf

Article link：http://dx.doi.org/10.1001/jamaoncol.2023.5013

Article Source：American Medical Association (AMA)。

Remark：

You can support us by donating, we would be very grateful.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

dportland Lv.4

Senior Member

post
reply
points
870

[JAMA] First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations Copy

Reply

Same Category

Latest Reply

Announcement

Enthusiastic users today

[JAMA] First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations